Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $12.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).The analyst comments "Net-net ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
